JPS63261162A - Blood cell separator - Google Patents
Blood cell separatorInfo
- Publication number
- JPS63261162A JPS63261162A JP62095183A JP9518387A JPS63261162A JP S63261162 A JPS63261162 A JP S63261162A JP 62095183 A JP62095183 A JP 62095183A JP 9518387 A JP9518387 A JP 9518387A JP S63261162 A JPS63261162 A JP S63261162A
- Authority
- JP
- Japan
- Prior art keywords
- filter
- blood
- blood cell
- cell separation
- blood cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000601 blood cell Anatomy 0.000 title claims abstract description 70
- 239000000463 material Substances 0.000 claims abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000000126 substance Substances 0.000 claims abstract description 18
- 238000000926 separation method Methods 0.000 claims description 46
- 229920006395 saturated elastomer Polymers 0.000 claims description 14
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 48
- 210000004369 blood Anatomy 0.000 abstract description 33
- 239000008280 blood Substances 0.000 abstract description 33
- 230000001954 sterilising effect Effects 0.000 abstract description 15
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 12
- -1 polyethylene terephthalate Polymers 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 abstract description 4
- 230000005855 radiation Effects 0.000 abstract description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 abstract description 4
- 238000010438 heat treatment Methods 0.000 abstract description 3
- 230000002093 peripheral effect Effects 0.000 abstract description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 abstract description 3
- 239000005020 polyethylene terephthalate Substances 0.000 abstract description 3
- 230000007423 decrease Effects 0.000 abstract description 2
- 238000001914 filtration Methods 0.000 abstract description 2
- 230000037452 priming Effects 0.000 abstract description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 abstract description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 230000006866 deterioration Effects 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000002195 soluble material Substances 0.000 abstract 1
- 238000003466 welding Methods 0.000 abstract 1
- 210000000265 leukocyte Anatomy 0.000 description 31
- 210000001772 blood platelet Anatomy 0.000 description 24
- 239000004745 nonwoven fabric Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 210000003743 erythrocyte Anatomy 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000005194 fractionation Methods 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 239000012209 synthetic fiber Substances 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002657 fibrous material Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 210000004880 lymph fluid Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 102100026735 Coagulation factor VIII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000004388 gamma ray sterilization Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000012784 inorganic fiber Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010526 radical polymerization reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
- B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
- B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- External Artificial Organs (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は血球分離フィルターを−１−要部とする血球分
離装置に関する。更に詳しくは、末梢崩、リンパ液、骨
髄液環＋ｆｎ球を含む血球浮遊液（以下、単に「血液」
と略称する）から、白血球、血小板を捕捉するフィルタ
ー、白血球を選択的に捕捉するフィルター、白血球のう
ち単球、顆粒球を捕捉するフィルター等の血球分離フィ
ルターを主要部とし、血液から白血球、１１１１小板を
除去したり、フィルターに捕捉された、白血球や白血球
内のリンパ球や顆粒球を採取する目的に使用される血球
分離装置に関する。DETAILED DESCRIPTION OF THE INVENTION (Industrial Field of Application) The present invention relates to a blood cell separation device having a blood cell separation filter as a main part. More specifically, peripheral fluid, lymph fluid, bone marrow fluid ring + blood cell suspension containing fn cells (hereinafter simply referred to as "blood")
The main parts are blood cell separation filters such as filters that capture white blood cells and platelets, filters that selectively capture white blood cells, and filters that capture monocytes and granulocytes among white blood cells. This invention relates to a blood cell separation device used for the purpose of removing platelets and collecting white blood cells, lymphocytes and granulocytes within the white blood cells captured by a filter.
（従来技術）
近年、全面輸血に代わって、赤血球、ｎｏ小板、＋ｍ漿
等治療目的に合った成分のみを選択的に輸＋ｍする成分
幅面が盛んに行われる様になって来た。(Prior Art) In recent years, instead of total blood transfusion, component-width transfusion, in which only components suitable for therapeutic purposes, such as red blood cells, platelets, and plasma, are selectively transfused has become popular.
また、最近では免疫療法を１」的とした白血球（特にリ
ンパ球）除去療法、活性化リンパ球輸注療法等も行われ
る様になって来ており、更にまた、血液から血球成分を
分画採取して血球の機能や表面抗原等を検査する事もし
ばしば行われる様になって来た。In addition, recently, leukocyte (especially lymphocyte) removal therapy and activated lymphocyte infusion therapy, etc., have started to be carried out, with immunotherapy as the primary focus, and furthermore, blood cell components have been differentially collected from blood. In recent years, testing of blood cell functions and surface antigens has become increasingly common.
それゆえ、血液から血球成分を各成分毎に効率良く、ま
た純度、機能等も良好に、かつ、簡便に分画する技術が
求められている。Therefore, there is a need for a technique for easily fractionating blood cell components from blood efficiently, with good purity, functionality, etc.
このように血液から血球成分を分画する公知の方法とし
ては、赤血球凝集剤をＩｌｌいる方法、遠心分離器を用
いる方法、繊維、不織イ１１、多孔体等から成る血球分
離フィルターを用いる方法等がある。Known methods for fractionating blood cell components from blood include a method using a hemagglutinating agent, a method using a centrifugal separator, and a method using a blood cell separation filter made of fiber, nonwoven material, porous material, etc. etc.
従来、血球成分の分画ｋｍは、−Ｌに遠心分離方法が用
いられていたが、分画操作に手間と時間を要するばかり
でなく、回収率や純度の点でも必ずしも充分な＋！Ｖｒ
ａｔ：を有しているとは占い難かりた。Conventionally, the centrifugation method has been used for -L fractionation km of blood cell components, but not only does the fractionation operation require time and effort, but it is not always sufficient in terms of recovery rate and purity. Vr
It was difficult to predict that he had at:.
これに対Ｉノ、近年、技術的にめざましく進歩して来た
曲球分画法に繊維、不織布、多孔体等を用いる血球分離
フィルター法かある。この方法は、血球の物質に対する
粘着性を利用した技術であり、ｍｎ球の種類により物質
に対する粘着性が異なっているＤｉを利用して、各血球
成分に分画しようとする技術である。この方法は、血球
の分画操作か非常ｋ”簡便であり、かつ短時間に操作が
終了し、また、回収率や純度の点でも優れたものである
。その１．ｂ、最近では、血球分画方法は遠心分離法か
ら血球分離フィルター法に徐々に移り変わりつつある。On the other hand, there is a blood cell separation filter method using fibers, nonwoven fabrics, porous materials, etc., which is a curved sphere fractionation method that has made remarkable technological progress in recent years. This method is a technique that utilizes the adhesion of blood cells to substances, and is a technique that attempts to fractionate each blood cell component using Di, which has different adhesion to substances depending on the type of MN cell. This method is very simple and can be completed in a short time, and is excellent in terms of recovery rate and purity. The fractionation method is gradually changing from centrifugation to blood cell separation filter method.
（発明が解決しようとする問題点）
血球分離フィルターを用いる血球分離技術は、上記した
様に優れた方法であるが、未解決の問題点、例えば、血
球分離フィルターを使用する而の生理的溶液によるプラ
イミンクの際に、気泡が抜り難い点、あるいは血球が損
傷を受は易い点、史には、血液を処理している間に血球
の粘着特性か経時的に変わってしまう点等を有している
。(Problems to be Solved by the Invention) Blood cell separation technology using a blood cell separation filter is an excellent method as described above, but there are still unresolved problems, such as physiological solutions using a blood cell separation filter. During priming, air bubbles may be difficult to remove, blood cells may be easily damaged, and the adhesive properties of blood cells may change over time during blood processing. are doing.
本発明のＬＩ的は、上記問題点に鑑み、血球分離フィル
ターを主要部とする血球分離装置を用い゛Ｃ血球を分画
するに当り、（１）ブライミング操作を簡便にする事、
（２）血球の受けるダメージを低減する事、（３）血球
分離フィルターの血球粘着挙動の経時変化を少なくする
事にあり、これらの性能を具備した１ｆ１１球分離装置
を提供１−る事にある。In view of the above-mentioned problems, the LI objectives of the present invention are to (1) simplify the briming operation when fractionating C blood cells using a blood cell separation device having a blood cell separation filter as the main part;
(2) to reduce damage to blood cells; (3) to reduce changes in blood cell adhesion behavior of blood cell separation filters over time; and to provide a 1f11 cell separation device that has these performances. .
（問題点を解決する為の手段）
木発明者らは上記目的に沿って鋭意研究を重ねた結果、
血球分離フィルターのフィルター材料を飽和含水生態１
−の湿潤状態にして、１５ ＜事により、ブライミンク
操作か簡便になるのみならず、驚くべき事に、血球の受
ける損傷の低減、血球粘着挙動の経時変化の抑制までを
も達成できるｌ（を見出【）、本発明をな１−に午っだ
。(Means for solving the problem) As a result of the wood inventors' intensive research in line with the above objectives,
Water-saturated ecology of filter material for blood cell separation filter 1
- By keeping it in a moist state of 15%, the briming operation is not only simpler, but surprisingly, it is also possible to reduce damage to blood cells and suppress changes in blood cell adhesion behavior over time. The present invention is based on the heading [).
すなわち木発明は、血球分間１フィルターを主要部とす
る■ｆｎ球分離装置において、少なくとも面記血球分離
フィルターのフィルター材料が、水または牛体にどっＣ
害の少ない水溶＋１物質の水溶液で飽和含水生態にの湿
潤状態に保持され、汁っ滅菌さ」１ている一ＩＶを特徴
とする血球公庫１装置である。In other words, the invention provides a fn cell separation device having a blood cell separation filter as a main part, in which at least the filter material of the blood cell separation filter is exposed to water or the body of a cow.
This blood cell collection device is maintained in a moist state in a saturated hydrated environment with an aqueous solution of a less harmful water-soluble substance and is sterilized.
木発明において、「血球分離フィルター」とは、末梢血
、リンパ液、骨髄液等の血球を含む血液から白血球、血
小板を捕捉する機能、白血球を選択的に捕捉する機能、
白血球のうち中１球、顆粒球を捕捉する機能、リンパ球
を捕捉する機能、リンパ球ザブセットを選択的に捕捉す
る機能Ａ−／、、； ＩＩｌ、球の一部を選択的に捕捉
する機能をイｊするフィルターであり、繊組状物質、織
布、不織布、ビーズ状物ｑ＋７、龜往体あるいはこわら
の材料の表面を化学処理、物理的処理、コーディング等
により改′（′ｆしたもの等を主要な材料どして用いた
フィルターを−ａう。In the invention, "blood cell separation filter" refers to a function that captures white blood cells and platelets from blood containing blood cells such as peripheral blood, lymph fluid, bone marrow fluid, etc., a function that selectively captures white blood cells,
A function to capture medium 1 cells and granulocytes among white blood cells, a function to capture lymphocytes, a function to selectively capture a subset of lymphocytes A-/,; IIl, a function to selectively capture a part of the cells It is a filter that is used to modify the surface of fibrous materials, woven fabrics, non-woven fabrics, bead-like materials, loose bodies, or stiff materials by chemical treatment, physical treatment, coating, etc. A filter using materials such as those as main materials.
また、「血球分離装置」どは、−に記血味分離フィルタ
ーを主構成要素とする装置であって、血液回路、唾液バ
ッグ等と血球分離フィルターとを紹み合わせたちのであ
り、全匍から白血球、血小板を除去するｌ」的、全面あ
るいは血小板Ｃ＝ Ｊ’Ｘ液中の白血球を除去する目的
、リンパ球を捕捉ｔ、・た接採取する１」的、リンパ球
ザブセット・を選択的に除去する「目的等、血球成分の
選択的除去、採取ｉ）るいは活性化に用いられるもので
ある。本装置１ごは、血液回路、＋ＩＩｔ液バッグ等の
他に、１１１Ｌ球成分（７）分離に必要な抗凝固剤、ク
ランプ、生理的溶液等各種機能を持った構成冴素をイ」
加する事が−（” ６る。In addition, a "blood cell separation device" is a device whose main component is a blood taste separation filter as described in -, which combines a blood circuit, saliva bag, etc. and a blood cell separation filter. For the purpose of removing white blood cells and platelets, from the entire surface or for removing white blood cells from the platelet C = J' It is used for the selective removal, collection, or activation of blood cell components.This device 1 includes a blood circuit, a +IIt fluid bag, etc., and a 111L cell component (7). We provide constituent agents with various functions such as anticoagulants, clamps, and physiological solutions necessary for separation.
Adding -(" 6ru.
「フィルター材料」とは、前記１血球分離フィルター構
成要素のうち、繊組状物質、織布、不織布、ビーズ状物
質、多孔体あるいはこれらの表面を化学処理、物理的処
理、コープインク等により改質したもの等を言い、血球
分離フィルターの主要な構成要素を言う。“Filter material” refers to fibrous materials, woven fabrics, non-woven fabrics, bead-like materials, porous materials, or those whose surfaces have been modified by chemical treatment, physical treatment, cope ink, etc., among the components of the blood cell separation filter. It refers to the main components of a blood cell separation filter.
「生体にとって害の少ない水溶性物質」とは、塩化す）
・リウム、炭酸ナトリウム、炭酸水素ナトリウム、リン
酸すトリウム、リン酸水素ナトリウム等の塩類、グリセ
リン、クエン酸ナトリウム、ゼラチン、カゼイン等の水
溶性有機化合物の様に水に溶ける物質て、しかも生体に
とって害の少ない物質であり、多量の場合には生体にと
って有害な物質であってもブライミング操作程度の簡単
な洗浄操作により、血球分離フィルター外に該物質を洗
い流す事ができ、少１ｄ゛の残存であわば生体にとって
害の少ない物質も含まれる。また、水に溶解させる事に
よって等張溶液を作り易い物質は特に好ましく用いられ
る。これらの物質は単独で用いても良く、混合して用い
ても良い。"Water-soluble substances that are less harmful to living organisms" are chlorinated substances)
・Substances that dissolve in water, such as salts such as lithium, sodium carbonate, sodium hydrogen carbonate, sodium phosphate, and sodium hydrogen phosphate, and water-soluble organic compounds such as glycerin, sodium citrate, gelatin, and casein, are harmful to living organisms. It is a harmless substance, and even if it is harmful to living organisms in large quantities, it can be washed out of the blood cell separation filter by a simple cleaning operation such as briming, and only a small amount of 1 d remains. It also includes substances that are less harmful to living organisms. In addition, substances that can be easily dissolved in water to form an isotonic solution are particularly preferably used. These substances may be used alone or in combination.
「飽和含水率以−Ｊ二の湿潤状態」とは、前記フィルタ
ー材料が完全に水または生体にとって害の少ない水溶性
物質の水溶液に浸清さね、た状態でも良いし、フィルタ
ー相料を前もって充分加湿し、材料自身の飽和含水量以
上の湿潤状態にするたけでも良い。要は、少なくともフ
ィルター材料がフィルター材料の飽和含水量と同等かそ
れよりも余計な水分にさらされていれば良いのであって
、その程度は問わない。The "wet state with a saturated water content of J2 or higher" may be a state in which the filter material has not been completely immersed in water or an aqueous solution of a water-soluble substance that is less harmful to living organisms, or a state in which the filter material has been soaked in water in advance. It is sufficient to sufficiently humidify the material so that the moisture content is higher than the saturated moisture content of the material itself. The point is that it is sufficient that the filter material is exposed to at least as much water as the saturated water content of the filter material or more than that, and the degree does not matter.
殺菌法には、加熱法（火炎法、乾熱法、高圧蒸気法、流
通蒸気法、煮沸法、間欠法）、濾過法、照射法（放射線
法、紫外線法、高周波法）、ガス法、薬液法等がある（
日本薬局方、第１１改正、一般試験法（７）滅菌法及び
無菌操作法）が、本発明で用いられる滅菌法は、フィル
ター材料が、その飽和含水率以上の湿潤状態を保てる滅
菌法が好ましく、フィルター材料が飽和含水量以上の湿
潤状態になっている時には滅菌の効果が無くなってしま
う様な滅菌方法は好ましくない。本発明で好んで用いら
れる滅菌方法は、高圧蒸気法、流通蒸気法、煮沸法、間
欠法、放射線法、高周波法、薬液法等であるが、高圧蒸
気法、放射線法は、特に好ましく用いられる。Sterilization methods include heating methods (flame method, dry heat method, high pressure steam method, flow steam method, boiling method, intermittent method), filtration method, irradiation method (radiation method, ultraviolet method, high frequency method), gas method, and chemical solution method. There are laws etc. (
According to the Japanese Pharmacopoeia, 11th revision, General Test Methods (7) Sterilization and Aseptic Operation Methods, the sterilization method used in the present invention is preferably a sterilization method that allows the filter material to be kept moist at a moisture content higher than its saturated moisture content. It is undesirable to use a sterilization method that loses its sterilization effect when the filter material is moistened beyond its saturated water content. Sterilization methods preferably used in the present invention include high pressure steam method, flow steam method, boiling method, intermittent method, radiation method, high frequency method, chemical liquid method, etc., and high pressure steam method and radiation method are particularly preferably used. .
本発明で血球分離フィルターのフィルター利料が飽和含
水率以上の湿潤状態を保持Ｉノている時に、ブライミン
グ操作が簡便になるのは頷けるが、何故血球の受ける損
傷が少なくなったり、血球粘着の経時的変化が少なくな
るのか、その理由は明らかで無い。Ｍｌ−測ではあるが
１．ＩＩＩＩ球の受けるダメージが減るのは、ブライミ
ング１〜る時の空気の残存が少なくなった結果、捕球が
空気に直接触れたり、乾燥状態のフィルタ・−材料に直
接血球が触第１る事が無くなったり、残存する気泡が物
理的ショックで消滅する時に受ける血球のダメージが少
なくなったりする事が考えらね、る。また、血球粘着特
性の経時的変化が少ない１工に関しては、フィルター材
料が１）ｆもって充分４潤状態になっている事によって
、唾液が接触した後、血液中の水分を吸収ｌノでフィル
ター材料表面が変化する様な事か無く、また、吸水によ
る血球の強固な粘着の様な現象も無くなる為である事等
が考えられる。In the present invention, it is understandable that the briming operation becomes easier when the filter material of the blood cell separation filter maintains a moist state higher than the saturated water content. It is not clear why the change over time decreases. Although it is an Ml-measurement, 1. The damage received by the III ball is reduced because there is less air left during briming, and the ball comes into direct contact with the air, and the blood cells come into direct contact with the dry filter material. I can't imagine that the damage to the blood cells would be reduced when the remaining air bubbles disappear due to physical shock. In addition, regarding the first method in which the blood cell adhesion properties change little over time, the filter material is in a sufficiently moist state with 1) f, so that after contact with saliva, the filter absorbs water in the blood. This is thought to be because there is no change in the surface of the material, and there is no phenomenon such as strong adhesion of blood cells due to water absorption.
以下、本発明を実施する態様について、輸血用の新鮮血
液から白血球を選択的に除去するフィルターを例にとっ
て説明する。DESCRIPTION OF THE PREFERRED EMBODIMENTS Modes for carrying out the present invention will be described below, taking as an example a filter that selectively removes leukocytes from fresh blood for transfusion.
手術時の出血に対し輸血をする事が多いが、特に大量の
輸血を要する時には赤血球の補充のみて無く、血小板や
血液凝固系因子の補充が要求される。この様な用途に用
いられる血液は採血して間も無い新鮮血であり、いわゆ
る生血と呼ばれるものである。しかしながら、この生血
には、新鮮な白血球が大量に含まれており、この白血球
が患者の組織を攻撃し、患者を重篤な状態に落とし入れ
る事がある。また、他人の白血球を縁り返し輸血すると
白血球に対する抗体ができ、輸血時に発熱、じん麻疹等
の副作用を起こす事がある。この様な副作用を防ぐ為に
用いられるのが白血球の選択除去フィルターであり、白
血球のみを選択的に除去し、赤血球、血小板、血漿は通
過させるフィルターである。Blood transfusions are often used to treat bleeding during surgery, but especially when a large amount of blood is required, not only red blood cells must be replenished, but platelets and blood coagulation factors must also be replenished. The blood used for such purposes is fresh blood that has just been collected, and is so-called fresh blood. However, this raw blood contains a large amount of fresh white blood cells, and these white blood cells may attack the patient's tissues and put the patient in a serious condition. Furthermore, if you transfuse another person's leukocytes, antibodies against the leukocytes will be produced, which may cause side effects such as fever and hives during the blood transfusion. To prevent such side effects, a white blood cell selective removal filter is used, which selectively removes only white blood cells while allowing red blood cells, platelets, and plasma to pass through.
１−記フイルターは、例えば編紐状物質の集合体である
不織布をフィルターの主要旧料として容器に充填して用
いるか、＃■小板の通過＋′ｌをより良くする為に不織
、／ＩＪ表面を親水性品分子でコープインクしたり、抗
血栓刊材料でコートする巾すある。The filter described in 1-1 may be used, for example, by filling a container with a non-woven fabric, which is an aggregate of knitted string-like substances, as the main material of the filter, or by using a non-woven fabric, which is an aggregate of braided material, in order to improve the passage of the small plates. /IJ surface may be coated with hydrophilic molecules or coated with antithrombotic material.
繊維の直径は、０．３μｍから２０７ｘ ｍ程度の物が
用いられ、１ａ維の素材としては、合成繊維、半合成ｉ
ａ維、天然繊維、無機繊維等が用いられる。The diameter of the fibers used is approximately 0.3 μm to 207 x m, and the materials for the 1a fibers include synthetic fibers and semi-synthetic fibers.
A fiber, natural fiber, inorganic fiber, etc. are used.
中でも合成繊維、例えばポリエチレンプレフタレート、
ナイロン、ポリプロピレン、ポリアクリロニトリル等の
繊維が好ましく用いられる。また、コート材としては、
ヒドロキシエチルアクリレート、ヒドロキシエチルメタ
クリレ−１・の様にヒドロキシル基を有する高分子材料
、ジエチルアミノエヂル（メタ）アクリレートとヒドロ
キシエチル（メタ）アクリレートとの共重合体の様に塩
基性含窒素官能基を有する高分子材料、ポリエーテルウ
レタン、アブコサン等を用いる事ができる。Among them, synthetic fibers such as polyethylene prephthalate,
Fibers such as nylon, polypropylene, and polyacrylonitrile are preferably used. In addition, as a coating material,
Polymer materials with hydroxyl groups, such as hydroxyethyl acrylate and hydroxyethyl methacrylate-1, and basic nitrogen-containing functional groups, such as copolymers of diethylaminoedyl (meth)acrylate and hydroxyethyl (meth)acrylate. It is possible to use polymeric materials such as polyether urethane, abscosan, etc.
上記したＪｌｌ１球分離フィルターのフィルター材料を
飽和含水率以上の湿潤状態にし、且つ滅菌する方法は、
例えば、フィルターに水、生理食塩水、グリセリン溶液
等の溶液を完全にあるいは部分的に充填して高圧蒸気滅
菌、γ線滅菌等の方法で滅菌する事によって達成できる
。また、フィルターに蒸気を通してフィルター材料を飽
和含水生態４の湿潤状態にしてから滅菌する事・もてき
るし、滅菌中、あるいは滅菌後に飽和含水率に達する様
に１ノても良い。要は、血球分離フィルターを使用する
直前までに、フィルター材料か飽和含水生態Ｌ：の湿潤
状態になっＣいれば良い。The method of keeping the filter material of the above-mentioned Jll1 bulb separation filter in a moist state with a saturated moisture content or higher and sterilizing it is as follows:
For example, this can be achieved by completely or partially filling the filter with a solution such as water, physiological saline, or glycerin solution, and sterilizing it by high-pressure steam sterilization, gamma ray sterilization, or the like. It is also possible to pass steam through the filter to bring the filter material into a moist state of saturated water content before sterilizing it, or to reach the saturated water content during or after sterilization. In short, just before using the blood cell separation filter, it is sufficient that the filter material is in a saturated hydrated state.
上記血球分離フィルターを使用する方法は、例えば、新
鮮面を血液回路を用いて血球分離フィルターに導人し、
血球分離フィルターを通過し、白血球を選択的に除去さ
れた血液を別のｍｌ＄１．バッグに受け、これを患者に
輸血する方ン人をとる’７Ｓ−ができる。必要があれば
、血球分離フィルターを！Ｊｆ面に洗浄したり、血球分
離フィルターに残った血液を回収するｌ、）の洗浄を行
っても良い。A method of using the blood cell separation filter described above includes, for example, introducing a fresh surface to a blood cell separation filter using a blood circuit,
The blood that has passed through the blood cell separation filter and from which white blood cells have been selectively removed is added to another ml of $1. You can collect the blood in a bag and use it to transfuse the blood into the patient. If necessary, use a blood cell separation filter! You may wash the Jf surface or wash the blood remaining in the blood cell separation filter (1).
上記した様に、予めフィルター材料が飽和含水率以上の
湿潤状態に保持された物を用いる事により、例えば、血
球分離フィルターが完全に生理食塩水で充填されていわ
ば、ブライミンダ操作が全く不要である１−７、湿潤状
態になっている事゛Ｃ血小板や赤血球の非特周粘着が抑
制され、これらの血球の機能低下が抑えられ、更に、フ
ィルター材料表面が血液中の水分を吸い取り、表面状態
を変化させる事により、血球の粘着挙動を変化させてし
まう事も無くなる。従って、−１−記血球分離フイルタ
ーを用いる事により、白血球を除去された輸血用の赤、
１１１１球、血小板の機能が損なわれる事が少なくなり
、自ｎｎ球の除去効率が悪くなる事も少なくなる。As mentioned above, by using a filter material that is kept moist in advance with a saturated water content or higher, for example, a blood cell separation filter can be completely filled with physiological saline, so that no blinding operation is required. 1-7. Being in a moist state prevents the non-specific adhesion of platelets and red blood cells, suppressing the functional decline of these blood cells, and furthermore, the surface of the filter material absorbs water in the blood and improves the surface condition. By changing this, it is also possible to avoid changing the adhesive behavior of blood cells. Therefore, by using the -1- blood cell separation filter, red blood for transfusion from which white blood cells have been removed,
The function of 1111 cells and platelets is less likely to be impaired, and the removal efficiency of own nn cells is less likely to deteriorate.
（発明の効果）
以ト述べた様に、本発明を用いる事により、血球分離フ
ィルターを主要部とする血球分離装置を用いた血球分画
の際のブライミンダ操作が非常に楽になり、血球の受け
るダメージが少なくなり、血球分離フィルターの粘着挙
動の紅時変化も少なくなる。(Effects of the Invention) As described above, by using the present invention, the blinding operation during blood cell fractionation using a blood cell separation device having a blood cell separation filter as the main part becomes very easy, and the Damage is reduced, and changes in the adhesion behavior of the blood cell separation filter over time are also reduced.
以下、実施例により、本発明を更に詳しく説明する。Hereinafter, the present invention will be explained in more detail with reference to Examples.
（実施例１）
白血球および血小板を除去し、赤血球を回収する目的の
フィルターを作製１ノて実験を行った。平均に径」、、
ｓμｍのポリエチレンテレフタレート製不織布を６７ｍ
ｍＸ６７ｍｍの止方形に切断したものを重ねて、添例図
面に示すようにカラム内にセットした３、不織布フィル
タ一層４は、２枚の角型の枠体２．２′を組み合わせて
できているカラム本体１の中にセラ］・されており、そ
の周辺部は圧着されている。３．３′はカラムの内側に
設けられた突起であり、不織布フィルターの中央部を部
分的に支持している。５は処理血液人Ｌ］、６は分離面
液出「１である。不織布フィルターの有効断面積は６０
ｍｍＸ６０ｍｍ＝３６００ｍｍ２であり、厚みは７ｍｍ
、重量は４．２ｇである。(Example 1) A filter for the purpose of removing white blood cells and platelets and recovering red blood cells was prepared and an experiment was conducted. Average diameter”,,
67m of sμm polyethylene terephthalate nonwoven fabric
The nonwoven fabric filters 3 and 4, which were cut into a rectangular shape of m x 67 mm and stacked one on top of the other and set in a column as shown in the attached drawing, are made by combining two rectangular frames 2 and 2'. The column body 1 is provided with a cellar, and its peripheral portion is crimped. 3.3' is a protrusion provided inside the column, which partially supports the central part of the nonwoven fabric filter. 5 is the processed blood volume L], 6 is the separation surface liquid flow volume 1.The effective cross-sectional area of the non-woven filter is 60
mmX60mm=3600mm2, thickness is 7mm
, the weight is 4.2g.
上記カラムに生理食塩水を充＠ｌノだ後、γ線を２．５
Ｍｒａｄ照射して滅菌した。このようにして作製したカ
ラムに、抗凝固剤ＡＣＤを添加したウシの新鮮面２ｋを
３０ｍ、ｅ／分の流速で流し、フィルターの白血球除去
率およびｒｆ＋を小板除去率を調べた（フィルター通過
前の白血球濃度と血小板濃度は各々、５８００ ／ ／
ｌｆｌと２５００００／μｐ、 ）。After filling the above column with physiological saline, γ-rays were applied at 2.5
It was sterilized by Mrad irradiation. Fresh bovine 2K supplemented with the anticoagulant ACD was passed through the column thus prepared at a flow rate of 30 m, e/min, and the leukocyte removal rate and rf+ platelet removal rate of the filter were examined (filter passage The previous white blood cell and platelet concentrations were each 5800//
lfl and 250000/μp, ).
その結果、白血球除去率は９０．２％、血小板除去率は
６３．２％であった。また、回収された赤血球の浸透圧
ぜい弱性試験結果は、フィルター通過前と変化が無かっ
た。また、血球分画操作を行なうに際して、ブライミン
グ操作は不要であった。白血球除去率と血小板除去率の
計算は以下の様にして行った。As a result, the leukocyte removal rate was 90.2% and the platelet removal rate was 63.2%. In addition, the osmotic vulnerability test results of the collected red blood cells were unchanged from before passing through the filter. Further, when performing the blood cell fractionation operation, a briming operation was not necessary. The leukocyte removal rate and platelet removal rate were calculated as follows.
白血球除去率（％）
血小板通過率（％）
（比較例１）
実施例１において、カラムに生理食塩水を充填せずにγ
線滅菌を行なった以外は実施例１と同様に行なった。Leukocyte removal rate (%) Platelet passage rate (%) (Comparative Example 1) In Example 1, γ
The same procedure as in Example 1 was performed except that wire sterilization was performed.
その結果、白血球除去率は８１．３％、血小板除去率は
４２．３％と、やや低かった。また、ブライミング操作
をしなかったところ、血液を流している際、カラム出口
から血液と一緒に気泡が出て来た。この様な気泡は、赤
血球を破壊する事か知られており、好ましく無い結果と
なった。As a result, the leukocyte removal rate was 81.3% and the platelet removal rate was 42.3%, which were somewhat low. Furthermore, when the briming operation was not performed, air bubbles came out along with the blood from the column outlet when blood was flowing. Such bubbles are known to destroy red blood cells, which is an undesirable result.
（実施例２）
赤血球、血小板は通過させ、白血球を除去する目的のフ
ィルターを作成して実験を行った。(Example 2) An experiment was conducted by creating a filter that allows red blood cells and platelets to pass through and removes white blood cells.
２−ヒドロキシエチルメタアクリレート（以下ＨＥＭＡ
と略称する）とジエチルアミノエチルメタアクリレート
（以下ＤＥＡＭＡと略称する）のコポリマーを通常の溶
液ラジカル重合によって合成した。重合条件としては、
エタノール中のモノマー濃度１モル／ＫＬで開始剤とし
てアゾイソブチロニトリル（ＡＩＢＮ）１／２００モル
／ｌ存在下、６０℃で８時間重合反応を行った。平均直
径１．７μｍのポリエチレンテレフタレート繊維よりな
る不織布（６０ｇ／ｍ２目イ」）を直径２５ｍｍの円形
に切断し、これを」−記のコポリマーの０．１％エタノ
ール溶液に浸した後、不織布に吸収された余分なポリマ
ー溶液は押ししぼって除去し、フィルターボルダ−に２
枚セットして乾燥空気を送りなから乾燥させた。コーデ
ィングした■ＩＥＭＡとＤ Ｅ Ａ Ｍ Ａとのコポリ
マー中のＤ ＥＡＭＡ単位の含量は５モル％とじた。2-Hydroxyethyl methacrylate (hereinafter referred to as HEMA)
A copolymer of DEAMA and diethylaminoethyl methacrylate (hereinafter referred to as DEAMA) was synthesized by conventional solution radical polymerization. The polymerization conditions are as follows:
Polymerization reaction was carried out at 60° C. for 8 hours in the presence of 1/200 mol/l of azoisobutyronitrile (AIBN) as an initiator at a monomer concentration of 1 mol/KL in ethanol. A nonwoven fabric made of polyethylene terephthalate fibers with an average diameter of 1.7 μm (60 g/m2) was cut into a circle with a diameter of 25 mm, and after soaking it in a 0.1% ethanol solution of the copolymer described in Remove the absorbed excess polymer solution by squeezing it out and place it in a filter boulder.
I set the sheets and dried them without blowing dry air. (2) The content of DEAMA units in the coded copolymer of IEMA and DEAMA was 5 mol%.
このようにしてコーティングした不織布を２枚フィルタ
ーボルダ−（柴田科学器械工業（株）製）にセットしく
厚み１．０ｍｍ）、そこへ生理食塩水１． ｍ ｌをし
み込ませてから滅菌袋に入れ、１２１℃、１気圧、２０
分の高圧蒸気滅菌を行った。Two sheets of the nonwoven fabric coated in this manner were set in a filter boulder (manufactured by Shibata Kagaku Kikai Kogyo Co., Ltd.) (thickness: 1.0 mm), and 1.0 mm of physiological saline was added thereto. ml, put it in a sterilized bag, and heat it at 121℃, 1 atm, 20
High-pressure steam sterilization was performed for minutes.
上記フィルターに抗凝固剤としてＡＣＤを添加したウシ
の新鮮面１０ｍｆｉをインフュージョンポンプを用いて
２ｍρ／ｍｉｎ、の一定流速で流した。フィルター通過
面の白血球濃度は６３００７μ℃、血小板濃度は２１０
０００／μｌてあった。10 mfi of fresh beef surface to which ACD was added as an anticoagulant was passed through the filter at a constant flow rate of 2 mρ/min using an infusion pump. The white blood cell concentration on the filter passing surface was 63007μ℃, and the platelet concentration was 210.
000/μl.
１ に
の結果、白血球除去率は９１．３％、血小板通過率く１
０〇−血小板除去率）は９６．０％てあった。得られた
血小板のコラーゲンによる凝集能は、フィルター通過前
の血液と変わらなかった。As a result of 1, the leukocyte removal rate was 91.3%, and the platelet passage rate was 1.
The platelet removal rate) was 96.0%. The collagen aggregation ability of the obtained platelets was not different from that of blood before passing through the filter.
（比較例２）
実施例２のフィルターを滅菌後乾燥して用いた以外は実
施例２と同様に実験した。その結果、白血球除去率は８
５．０％、血小板通過率は８４゜０％と低めであった。(Comparative Example 2) An experiment was carried out in the same manner as in Example 2 except that the filter of Example 2 was used after being sterilized and dried. As a result, the leukocyte removal rate was 8
5.0%, and the platelet passage rate was low at 84.0%.
また、血小板通過率の経時変化を追って行ったところ、
最初の２分程度は５０〜６０％の間でやや低く、経時的
に通過率か良くなる事がわかった。In addition, when we followed changes in platelet passage rate over time, we found that
It was found that the passage rate was rather low at 50 to 60% for the first two minutes, and improved over time.
図は、実施例１および比較例１に用いた血球分離フィル
ターの構造を示す断面模式図である。
１、カラム本体 ５ 処理血液人［Ｉ２．２’
、枠体 ６５分分離液出「１３．３’ 、突
起
４、不織布フィルタ一層The figure is a schematic cross-sectional view showing the structure of the blood cell separation filter used in Example 1 and Comparative Example 1. 1. Column body 5. Processed blood [I2.2'
, Frame 65 minutes separation liquid output "13.3', 4 protrusions, non-woven filter single layer
Claims (1)
て、少なくとも前記血球分離フィルターのフィルター材
料が、水または生体にとって害の少ない水溶性物質の水
溶液で飽和含水率以上の湿潤状態に保持され、且つ滅菌
されている事を特徴とする血球分離装置。In a blood cell separation device having a blood cell separation filter as a main part, at least the filter material of the blood cell separation filter is maintained in a moist state with a saturated water content or higher with water or an aqueous solution of a water-soluble substance that is less harmful to living organisms, and is sterilized. A blood cell separation device characterized by:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62095183A JP2521090B2 (en) | 1987-04-20 | 1987-04-20 | Blood cell separator |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62095183A JP2521090B2 (en) | 1987-04-20 | 1987-04-20 | Blood cell separator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63261162A true JPS63261162A (en) | 1988-10-27 |
| JP2521090B2 JP2521090B2 (en) | 1996-07-31 |
Family
ID=14130637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62095183A Expired - Lifetime JP2521090B2 (en) | 1987-04-20 | 1987-04-20 | Blood cell separator |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2521090B2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03173825A (en) * | 1989-09-18 | 1991-07-29 | Terumo Corp | Filter for purifying blood platelet |
| JP2008224319A (en) * | 2007-03-09 | 2008-09-25 | Olympus Corp | Flocculation determining container of blood corpuscles |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5469291A (en) * | 1977-11-15 | 1979-06-04 | Kawasumi Lab Inc | Method of sterilizing artificial kidney |
| JPS5523620A (en) * | 1978-08-05 | 1980-02-20 | Nippon Columbia Co Ltd | Headphone receiver |
| JPS56161059A (en) * | 1980-05-16 | 1981-12-11 | Kuraray Co | Device for treating preserved blood |
| JPS57145663A (en) * | 1981-03-05 | 1982-09-08 | Asahi Chemical Ind | Apparatus and method for catching and sampling lymph |
| JPS603367A (en) * | 1983-06-18 | 1985-01-09 | 高木 金一 | Fluid pressure support |
-
1987
- 1987-04-20 JP JP62095183A patent/JP2521090B2/en not_active Expired - Lifetime
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5469291A (en) * | 1977-11-15 | 1979-06-04 | Kawasumi Lab Inc | Method of sterilizing artificial kidney |
| JPS5523620A (en) * | 1978-08-05 | 1980-02-20 | Nippon Columbia Co Ltd | Headphone receiver |
| JPS56161059A (en) * | 1980-05-16 | 1981-12-11 | Kuraray Co | Device for treating preserved blood |
| JPS57145663A (en) * | 1981-03-05 | 1982-09-08 | Asahi Chemical Ind | Apparatus and method for catching and sampling lymph |
| JPS603367A (en) * | 1983-06-18 | 1985-01-09 | 高木 金一 | Fluid pressure support |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03173825A (en) * | 1989-09-18 | 1991-07-29 | Terumo Corp | Filter for purifying blood platelet |
| JP2008224319A (en) * | 2007-03-09 | 2008-09-25 | Olympus Corp | Flocculation determining container of blood corpuscles |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2521090B2 (en) | 1996-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2202491T3 (en) | FILTRATION MATERIAL FOR THE ELIMINATION OF LEUCOCITS. | |
| EP0267286B1 (en) | Filter medium for selectively removing leucocytes | |
| JP2002500931A (en) | Biological fluid treatment system | |
| US5540841A (en) | Cardioplegia filter and method for processing cardioplegia fluid | |
| CN1268893A (en) | Leukocyte-removing filter material | |
| JPH067429A (en) | Blood filter medium | |
| US6193896B1 (en) | Method for removal of leucocytes from blood | |
| JPH0725776A (en) | Filter material for selectively removing leukocyte | |
| JPH04187206A (en) | Leucocyte separator and production of leucocyte separating material | |
| JP3250833B2 (en) | Leukocyte selective capture filter material | |
| JP2002087971A (en) | Method for separating living body tissue-regenerating cell and device for the same | |
| JP2003304865A (en) | Method for separating cell | |
| JPS63261162A (en) | Blood cell separator | |
| JPH0780062A (en) | Endotoxin removing device and production of purified blood | |
| JP2613249B2 (en) | Leukocyte removal material and leukocyte removal filter | |
| JP3459836B2 (en) | Platelet purification filter | |
| JP3272099B2 (en) | Bradykinin adsorbent | |
| JP3768009B2 (en) | Blood filter and manufacturing method thereof | |
| JP2003190276A (en) | Virus and white blood cell selective removal method, removal material and remover | |
| JP2854857B2 (en) | Leukocyte removal filter coated with chitosan or modified chitosan | |
| JP4175527B2 (en) | Method and device for removing lymphocytes in blood | |
| JP3147343B2 (en) | Method for producing hydrophilic filter material | |
| JP2003320026A (en) | Cylindrical leukocyte remover and leukocyte removing system | |
| JP2003116521A (en) | Method and apparatus for separating and concentrating sp cell | |
| JP3467757B2 (en) | Leukocyte removal filter |